The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD

NCT ID: NCT02473783

Last Updated: 2018-01-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-31
• Study Completion Date: 2012-11-30

Brief Summary

Objectives:

1. To evaluate the relationship between improvement of Hamilton Depression Rating Scale (HAMD) score and basal SERT availability (binding potential) for the prognosis of MDD subjects being treated with Sertraline HCl

2. To evaluate the SERT availability by means of I-123-ADAM SPECT imaging study for assisting in detecting MDD

3. To evaluate the relationship between basal HAMD score and basal SERT availability for MDD subjects

4. To evaluate the relationship between basal HAMD somatic subscale score and basal SERT availability for MDD subjects

5. To evaluate the relationship between change of SERT availability and change of HAMD score for MDD patients being treated with Sertraline HCl

Detailed Description

Background:

Serotonin transporter (SERT) plays an important role in the pathophysiology of psychiatric disorders such as anxiety and depression and is the primary target of the selective serotonin reuptake inhibitors (SSRIs) which are posited to exert their effect in treating psychiatric disorders aforementioned by this mechanism. I-123-ADAM is a selective radioligand for imaging SERT using SPECT. Research showed that it displayed an extremely high binding affinity to SERT sites. Previous literature also suggested the potential role of I-123-ADAM SPECT as useful in understanding how serotonin system affected depression. This study aims to evaluate the SERT availability by means of I-123-ADAM SPECT imaging study in drug-free subjects for prognosing MDD treatment and assisting in detecting MDD.

Methods:

We enrolled patients who had major depressive disorder but was free from prior antidepressant medication for at least 5 times of elimination half-lives and healthy controls. The patients with major depressive disorder (N=20) received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. All healthy subjects (N=17) had only basal I-123-ADAM SPECT. The relationship between improvement of depressive symptoms and basal SERT availability for the prognosis of MDD subjects being treated with Sertraline HCl will be analyzed. In addition, the association between the efficacy of treatment with Sertraline HCl and the change of SERT availability will also be investigated. The control group were selected in order to distinguish the difference of basal SERT binding potential of I-123-ADAM between healthy and MDD subjects.

Conditions

Major Depressive Disorder

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Treatment Group

The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.

Group Type: EXPERIMENTAL

Sertraline HCl

Intervention Type: DRUG

The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.

I-123-ADAM SPECT

Intervention Type: OTHER

The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.

Interventions

Sertraline HCl

The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.

Intervention Type: DRUG

I-123-ADAM SPECT

The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.

Intervention Type: OTHER

Other Intervention Names

Zoloft

Eligibility Criteria

Inclusion Criteria

• For MDD subjects

1. Subject meets the DSM-IV criteria for MDD

2. Subject has a minimum score of 18 on the 17-item HAMD total score

3. Subject has a minimum score of 2 on item 1, depressed mood, of HAMD

4. Subject is free from prior antidepressant medication for at least 5 times of elimination half-lives

For healthy subjects

1. Subject without past or current neuropsychiatric illnesses based on a clinical interview including Mini-International Neuropsychiatric Interview (M.I.N.I.) and a physical examination

2. Subject without exposure to psychotropic medication or other substances known to affect the brain serotonin system within 1 year prior to entering the study

Exclusion Criteria

1. Subject with history of any co-morbid neuropsychiatric disease

2. Subject with history of treatment resistant to at least two full doses and courses of antidepressant medication

3. Subject with history of alcohol or substance dependence or abuse

4. Subject with allergic history to the investigational products

5. Subject with severe cardiovascular disease or cerebrovascular disease which is judged by investigators for safety concerns as inappropriate for this study

6. Subject with malignancy within past 5 years

7. Subject with any diseases judged by investigators as inappropriate for this study

8. Female subject being pregnant, nursing, or lactating

9. Female subject of childbearing potential not using a medically acceptable form of birth control

10. Subject is unable to undergo MRI scan to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations

11. Subject participated in any investigational drug trial within 4 weeks before entering this study

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Atomic Research Institute, Taiwan

OTHER

Sponsor Role: collaborator

Tri-Service General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Chin-Bin Yeh, MD, PhD

Director of Department of Psychiatry

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Chin-Bin Yeh, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Tri-Service General Hospital

Other Identifiers

INEI-1A20090409

Identifier Type: -

Identifier Source: org_study_id